A healthcare provider may prescribe abiraterone acetate (Zytiga™) to treat advanced prostate cancer that has spread to other parts of the body and has not responded to other medical treatments.
Available in the form of a tablet, abiraterone is taken once daily. It works by decreasing the amount of testosterone produced in the adrenal glands and in the prostate cancer cells. Testosterone stimulates the growth of prostate cancer cells. By lowering testosterone levels, abiraterone helps to slow down the growth of cancer cells.
Although most people tolerate abiraterone well, side effects may occur and can include muscle aches, joint swelling, and hot flushes.
(For more information on abiraterone acetate, click Abiraterone. This full-length article takes a closer look at this prescription medicine, including dosing guidelines and general safety precautions to be aware of before beginning treatment.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Zytiga Web site. Available at: http://www.zytiga.com/. Accessed June 16, 2011.
Food and Drug Administration (FDA) news release. FDA approves Zytiga for late-stage prostate cancer. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm. Accessed June 16, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed June 17, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click